Biller holds a J. D. from Yale Law School and a B.A. from Brown University and will be responsible for global legal strategy as well as serve on the company's executive committee.
He joined Celgene in 2011 and was most recently senior vice president, tax and treasury and served as Celgene's treasurer.
Prior to joining Celgene, Biller managed a global legal team of more than 100 professionals and was general counsel, chief tax officer and secretary at Bunge Ltd., a publicly traded agriculture and food company.
Earlier in his career, Biller held roles of increasing responsibility at Alcon, Inc. and began his legal career at Hopkins and Sutter where he became a partner and continued to serve as a partner at Foley and Lardner after the firms merged.
Celgene is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialisation of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP